TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03836001

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Serlopitant Tablet
Description: Serlopitant is a small molecule, highly selective NK1-R (neurokinin-1 receptor) antagonist. Two critical mediators of the urge to scratch are Substance P, or SP, and its receptor, NK1-R. SP is a naturally occurring peptide in the tachykinin neuropeptide family. Tachykinins have a broad range of functions in the nervous and immune systems. SP binding of NK1-R has been shown to be a key mediator of sensory nerve signaling, including the itch-scratch reflex and the vomiting reflex.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: The placebo is a tablet that looks like a drug but has no drug or other active ingredient in it.
Study: NCT00392379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Lozenges
Description: Nicotine lozenges, 4 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo lozenge
Description: Placebo lozenge
Study: NCT04271644

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCMA CAR-T cells
Description: BCMA CAR-T cell therapy
Study: NCT05304780

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: needs-tailored nurse-led recovery program
Description: The needs-tailored nurse-led recovery program were divided into five major stages of care, which were build partnership, conduct integrated needs assessment, set needs-based recovery goals and provide empowerment-oriented care, conduct continuous monitoring of goals, and conduct effectiveness evaluations.
Study: NCT03443986

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training associated with vibration
Description: The workout will be held three times a week and will last a total of 12 weeks (3 months) for 45 minutes, where there will be 5 minutes of heating, 19 minutes of exercise with load, 16 minutes of vibration and 5 minutes of slowdown.
Study: NCT02029378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Study: NCT01123993

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Music CD
Description: During 4-week interventional period of each group, a researcher gives a CD to care giver and advises him/her to open the music for patient for at least 60 minutes daily, after dinner to bedtime. Meanwhile, the care giver notes the exact duration that patient actually listens to it in the calendar provided and returns the CD and document to the researcher at the end of interventional period.
Study: NCT04375319

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCT
Description: OCT can provide clear in vivo imaging and evaluate the vascular repair after stent implantation by measuring the optical echo of near-infrared light reflection
Study: NCT00361933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valganciclovir
Description: valganciclovir open label, two 450mg tablets orally, twice a day
Study: NCT03443986

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Resistance training associated with vibration sham
Description: he workout will be held three times a week and will last a total of 12 weeks (3 months) for 45 minutes, where there will be 5 minutes of heating, 19 minutes of exercise with load, 16 minutes of vibration sham and 5 minutes of slowdown.
Study: NCT00709709

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: multislice coronary scan
Description: multislice coronary scan
Study: NCT03935113

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio taping
Description: In KT group, KT was applied using the insertion-origin muscle and space-correction technique of affected upper limb with stroke patients.
Study: NCT00067938

Intervention type: DRUG
Group type: OTHER
Intervention: lamotrigine
Description: Lamotrigine
Study: NCT00392145

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard IV rehydration
Description: A 20 mL/kg 0.9% normal saline bolus (maximum 999 mL) will be administered over 1 hour. This will be followed by D5-0.9% normal saline at a maintenance rate (maximum 55 mL/hr).
Study: NCT01524718

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Imaging with two X-ray image intensifiers
Description: Two fluoroscopy apparatus one in the AP plane and the other as the axial plane.
Study: NCT02755714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide spray
Description: The patient will - or will not - receive Ipratropium bromide spray (MDI) 20 μg given through a plastic spacer two puffs 1 hour before a continuous laryngoscopy exercise test (CLE-test)
Study: NCT02247752

Intervention type: OTHER
Group type: OTHER
Intervention: inactive carrier
Description: Yearly demographic, clinic, biologic and ultrasonic data collection realized during usual follow-up as recommended.~Yearly centralisation of a complementary biological analysis in Paul Brousse Hospital laboratory of virology.
Study: NCT03904303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A 06 ad
Description: Colonic cleansing before colonoscopy and CT colonografi

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A 06 ad
Description: Colonic cleansing before colonoscopy and CT colonografi
Study: NCT03992586

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wearing pink glasses
Description: Wearing pink-colored lenses

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Wearing clear glasses
Description: Wearing clear glasses
Study: NCT02475954

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TH-CBT
Description: The TH-CBT group will receive the study intervention and standard care. The study treatment has been previously manualized and modified for remote administration, as described in the introduction to the revised application.12 PD Veterans will receive 10 weekly individual sessions (60 minutes each) of CBT, delivered via Video-to-Home (V2H).

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Care
Description: Standard Care is defined as medical and psychiatric treatment provided by patients' personal doctors (e.g., neurologists, psychiatrists, therapists). Veterans will continue to receive routine clinical care and will remain on all depression treatments that they were receiving prior to their study (e.g., stable anti-depressant medications, established psychotherapy, clinical monitoring).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Standard Care is defined as medical and psychiatric treatment provided by patients' personal doctors (e.g., neurologists, psychiatrists, therapists). Veterans will continue to receive routine clinical care and will remain on all depression treatments that they were receiving prior to their study (e.g., stable anti-depressant medications, established psychotherapy, clinical monitoring).
Study: NCT00392145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapid intravenous rehydration (RIVR)
Description: A 60 mL/kg 0.9% normal saline bolus (maximum 999 mL) over 1 hour will be administered. This will be followed by D5-0.9% normal saline at a maintenance rate (maximum 55 mL/hr).
Study: NCT01607827

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Polyp removal upon insertion and withdrawal
Description: Endoscopic procedures:~All polypectomies in the study groups were performed using the same techniques as in the standard care of non-study patients, using snare loops, hot biopsy forceps, with and without submucosal injection of saline/epinephrine. Polyps larger than 3 mm were removed by snare, polyps smaller than 4 mm were removed by cold biopsy. There were no differences upon insertion or withdrawal.~The endoscopist removed all visible polyps instantly regardless whether advancing the instrument to the cecum or pulling back.

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Polyp removal upon withdrawal only
Description: Endoscopic procedures:~All polypectomies in the study groups were performed using the same techniques as in the standard care of non-study patients, using snare loops, hot biopsy forceps, with and without submucosal injection of saline/epinephrine. Polyps larger than 3 mm were removed by snare, polyps smaller than 4 mm were removed by cold biopsy. There were no differences upon insertion or withdrawal.~The endoscopist advanced the endoscope to the cecum without removing polyps. Upon withdrawal, all visible polyps were removed successively by standard techniques.
Study: NCT01227967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amantadine, Ribavirin, Oseltamivir
Description: Subjects were prescribed the medication twice daily for 5 days, and each dose consisted of one capsule of Oseltamivir 75 mg, three capsules of Ribavirin 200 mg for total of 600 mg, and one capsule of Amantadine 100 mg.
Study: NCT00301366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alpha-1 proteinase inhibitor (human)
Description: 60 mg/kg weekly for 20 weeks
Study: NCT00537225

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: tailored multifactor CVD risk reduction
Study: NCT02630043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolcapone
Description: Tolcapone is an oral agent that will be administered every day of each 21-day cycle during Cycle 1 and in combination with oxaliplatin during cycles 2-5 given IV on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin will be given starting in Cycle 2 at 100 mg/m2 IV on Day 1 of each 21-day cycle
Study: NCT01227967

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir
Description: Subjects were prescribed the medication twice daily for 5 days, and each dose consisted of one capsule of Oseltamivir 75 mg.
Study: NCT04604132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Derazantinib
Description: Derazantinib was administered orally at a dose of 300 mg once daily as monotherapy in the Substudy 1 (Cohort 1.1).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Derazantinib-paclitaxel-ramucirumab combination
Description: Derazantinib was administered orally at a dose of 200 mg once daily in combination with paclitaxel and ramucirumab.~Paclitaxel was administered intravenously at a dose of 80 mg/m² on days 1, 8, and 15 of a 28-day cycle in combination with ramucirumab.~Ramucirumab was administered intravenously at a dose of 8 mg/kg every 2 weeks in combination with paclitaxel.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Derazantinib-paclitaxel-ramucirumab combination
Description: Derazantinib was administered orally at a dose of 300 mg once daily in combination with paclitaxel and ramucirumab.~Paclitaxel was administered intravenously at a dose of 80 mg/m² on days 1, 8, and 15 of a 28-day cycle in combination with ramucirumab.~Ramucirumab was administered intravenously at a dose of 8 mg/kg every 2 weeks in combination with paclitaxel.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Derazantinib
Description: Derazantinib was administered orally at a dose of 200 mg twice daily as monotherapy in the Substudy 1 (Cohort 1.3).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Derazantinib
Description: Derazantinib was administered orally at a dose of 300 mg once daily as monotherapy in the Substudy 1 (Cohort 1.2).
Study: NCT00952380

Intervention type: DRUG
Group type: OTHER
Intervention: dalteparin
Description: dalteparin subcutaneous injection
Study: NCT04821505

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: didactic classroom instruction on improving ones lifestyle through healthier diet, exercise and control of substance use.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation
Description: TM is described as simple technique practiced 20 minutes twice a day for deep rest and relaxation.
Study: NCT02206178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine combination with acetaminophen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: N-acetylcysteine combination with acetaminophen
Study: NCT02627040

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: InterTan Intertrochanteric Nail
Description: Cephalomedullary fixation of intertrochanteric fracture with an InterTan Intertrochanteric Nail

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gamma 3 Intertrochanteric Nail
Description: Cephalomedullary fixation of intertrochanteric fracture with an Gamma 3 Intertrochanteric Nail
Study: NCT02206178

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03364829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol/Glycopyrronium
Study: NCT03131830

Intervention type: OTHER
Intervention: Online-based questionnaire
Description: Participants receive a web-link to a questionnaire, which is active for 3 months

Intervention type: OTHER
Intervention: Online-based questionnaire
Description: Participants receive a web-link to a questionnaire, which is active for 3 months

Intervention type: OTHER
Intervention: Online-based questionnaire
Description: Participants receive a web-link to a questionnaire, which is active for 3 months

Intervention type: OTHER
Intervention: Online-based questionnaire
Description: Participants receive a web-link to a questionnaire, which is active for 3 months
Study: NCT02521896

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Steerable Sheath System
Description: The Vado™ Steerable Sheath consists of a dilator and steerable sheath which are designed to provide intracardiac access and flexible catheter positioning in the cardiac anatomy.
Study: NCT01532141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: 50 mg BIA 9-1067 (single-dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: 50 mg BIA 9-1067 (single-dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: 50 mg BIA 9-1067 (single-dose)
Study: NCT00183729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Memantine dosage is started at 10 mg daily and is increased at Week 1 as tolerated to 10 mg two times a day.
Study: NCT01532141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rasagiline
Description: 1 mg rasagiline (single-dose)
Study: NCT01231412

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic PBSCT
Study: NCT00183729

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo distribution is planned to mimic the active drug.
Study: NCT04479319

Intervention type: DIAGNOSTIC_TEST
Intervention: Thorax CT
Description: Subjects in all arms have a Thorax CT and RT-PCR for SARS-CoV-2.

Intervention type: DIAGNOSTIC_TEST
Intervention: Thorax CT
Description: Subjects in all arms have a Thorax CT and RT-PCR for SARS-CoV-2.

Intervention type: DIAGNOSTIC_TEST
Intervention: Thorax CT
Description: Subjects in all arms have a Thorax CT and RT-PCR for SARS-CoV-2.
Study: NCT03199755

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACT
Description: Current approved drug for treating malaria
Study: NCT01231412

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic PBSCT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic PBSCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given PO or IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Description: Given PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given PO or IV
Study: NCT03199755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DLA1
Description: Experimental drug treatment, single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DLA2
Description: Experimental drug treatment, doubled the dose of DLA1.
Study: NCT01231412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo allogeneic PBSCT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo allogeneic PBSCT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo allogeneic PBSCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Given PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Total-Body Irradiation
Description: Undergo TBI

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI
Study: NCT02316834

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMN 673
Description: BMN673 given at a dose of 1 mg orally once daily.~Participants begin taking BMN 673 tablets by mouth every day, starting on the day of scheduled laparoscopy. Participants take the study drug for at least 7 days before scheduled tumor reduction surgery.
Study: NCT02924701

Intervention type: OTHER
Intervention: Blood samples, fibroscan and questionaires
Study: NCT01201213

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: local anaesthetic injection
Description: Single bolus of drug for pain relief in early labour

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: local anaesthetic injection
Description: Single bolus of drug for pain relief in early labour

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: local anaesthetic injection
Description: Single bolus of drug for pain relief in early labour

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: local anaesthetic injection
Description: Single bolus of drug for pain relief in early labour

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: local anaesthetic injection
Description: Single bolus of drug for pain relief in early labour

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: local anaesthetic injection
Description: Single bolus of drug for pain relief in early labour
Study: NCT00166387

Intervention type: PROCEDURE
Intervention: Blood draw
Description: A single blood draw.
Study: NCT00032084

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: smoking cessation intervention
Description: Physician will deliver the smoking cessation advice, reinforce the established quit date (no sooner than seven days after starting bupropion/placebo), and will distribute patient educational materials and all pharmacotherapy

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: smoking cessation intervention
Description: Physician will deliver the smoking cessation advice, reinforce the established quit date (no sooner than seven days after starting bupropion/placebo), and will distribute patient educational materials and all pharmacotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupropion hydrochloride
Description: 150 mg/day on Days 1-3, 300 mg/day on Day 4-77

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nicotine
Description: 21 mg patch/day for Weeks 2-7; 14 mg patch/day for Weeks 8-9; 7 mg patch/day for Weeks 10-11.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: nicotine
Description: 21 mg patch/day for Weeks 2-7; 14 mg patch/day for Weeks 8-9; 7 mg patch/day for Weeks 10-11.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: psychosocial assessment and care
Description: The nurse/CRA will debrief the patients after the brief physician intervention and will follow-up with a series of 5 phone calls to provide booster advice. All advice will be based on the stage of change model (i.e., tailored to the patient's readiness to quit and/or stay off cigarettes).

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: psychosocial assessment and care
Description: The nurse/CRA will debrief the patients after the brief physician intervention and will follow-up with a series of 5 phone calls to provide booster advice. All advice will be based on the stage of change model (i.e., tailored to the patient's readiness to quit and/or stay off cigarettes).
Study: NCT01384292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-118
Description: 12.5 mg oral tablet once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-118
Description: 25 mg oral tablet once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral treatment
Study: NCT03119012

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: 75mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: 75mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: 120mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: 120mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: 100mg/day